AUM Biosciences is already in collaboration with several high profile pharmaceutical companies for various research and drug trial applications.
Collaboration with A*STAR’s Experimental Therapeutics Centre (ETC) – AUM has global rights to develop, commercialise and manufacture ETC-206 in all indications. ETC-206 was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC) and Duke-NUS Medical School (a partnership between Duke University School of Medicine and the National University of Singapore). ETC-206 is the first in AUM’s pipeline of novel targeted therapies with the potential to be developed both independently and in combination with other therapies.
Cyclica, based in Toronto, is a biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. In this strategic partnership, AUM will deploy its drug development expertise, including a biomarker-driven approach, and utilize Cyclica’s integrated AI-augmented and structure-based platform, Ligand Design and Ligand Express, which together will design advanced lead-like molecules that minimize unwanted off-target effects while providing a holistic understanding of a molecule’s activity through integrated systems biology and structural pharmacogenomics. For more information, please visit www.cyclicarx.com/.
Collaboration with A*STAR’s Experimental Therapeutics Centre (ETC) – AUM has global rights to develop, commercialise and manufacture ETC-206 in all indications. ETC-206 was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC) and Duke-NUS Medical School (a partnership between Duke University School of Medicine and the National University of Singapore). ETC-206 is the first in AUM’s pipeline of novel targeted therapies with the potential to be developed both independently and in combination with other therapies.
Cyclica, based in Toronto, is a biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. In this strategic partnership, AUM will deploy its drug development expertise, including a biomarker-driven approach, and utilize Cyclica’s integrated AI-augmented and structure-based platform, Ligand Design and Ligand Express, which together will design advanced lead-like molecules that minimize unwanted off-target effects while providing a holistic understanding of a molecule’s activity through integrated systems biology and structural pharmacogenomics. For more information, please visit www.cyclicarx.com/.